Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 12 studies | 38% ± 17% | |
microglial cell | 11 studies | 33% ± 11% | |
oligodendrocyte | 11 studies | 26% ± 8% | |
glutamatergic neuron | 9 studies | 41% ± 23% | |
astrocyte | 9 studies | 26% ± 10% | |
oligodendrocyte precursor cell | 9 studies | 26% ± 11% | |
myeloid cell | 8 studies | 34% ± 14% | |
GABAergic neuron | 7 studies | 40% ± 16% | |
endothelial cell | 6 studies | 28% ± 14% | |
interneuron | 6 studies | 34% ± 17% | |
neuron | 5 studies | 39% ± 18% | |
dendritic cell | 5 studies | 28% ± 2% | |
ciliated cell | 5 studies | 23% ± 7% | |
monocyte | 5 studies | 34% ± 13% | |
type I pneumocyte | 5 studies | 23% ± 9% | |
classical monocyte | 4 studies | 23% ± 7% | |
epithelial cell | 4 studies | 33% ± 18% | |
GABAergic interneuron | 3 studies | 23% ± 9% | |
granule cell | 3 studies | 30% ± 11% | |
alveolar macrophage | 3 studies | 42% ± 13% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 2503.31 | 577 / 578 | 97% | 15.55 | 1117 / 1155 |
breast | 99% | 1519.68 | 453 / 459 | 98% | 13.98 | 1092 / 1118 |
esophagus | 95% | 1940.03 | 1371 / 1445 | 100% | 28.69 | 183 / 183 |
stomach | 96% | 1389.00 | 345 / 359 | 98% | 13.39 | 279 / 286 |
bladder | 95% | 1240.86 | 20 / 21 | 98% | 13.30 | 493 / 504 |
uterus | 97% | 1005.35 | 165 / 170 | 96% | 13.77 | 440 / 459 |
intestine | 94% | 1696.47 | 907 / 966 | 98% | 11.65 | 515 / 527 |
prostate | 96% | 1573.48 | 236 / 245 | 94% | 10.51 | 473 / 502 |
thymus | 100% | 1481.15 | 651 / 653 | 89% | 7.34 | 537 / 605 |
brain | 91% | 1415.75 | 2416 / 2642 | 97% | 10.89 | 681 / 705 |
skin | 100% | 6506.05 | 1801 / 1809 | 88% | 8.42 | 416 / 472 |
pancreas | 93% | 851.54 | 305 / 328 | 92% | 8.65 | 164 / 178 |
ovary | 91% | 883.21 | 163 / 180 | 93% | 10.77 | 402 / 430 |
kidney | 91% | 863.85 | 81 / 89 | 78% | 5.50 | 706 / 901 |
liver | 100% | 1191.33 | 225 / 226 | 50% | 3.22 | 202 / 406 |
adrenal gland | 98% | 919.70 | 252 / 258 | 36% | 1.70 | 82 / 230 |
spleen | 100% | 2249.67 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 6.62 | 1 / 1 |
adipose | 99% | 1272.43 | 1193 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 3328.85 | 907 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 96% | 16.76 | 43 / 45 |
blood vessel | 70% | 605.91 | 936 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 69% | 7.99 | 20 / 29 |
muscle | 36% | 235.19 | 292 / 803 | 0% | 0 | 0 / 0 |
heart | 35% | 238.57 | 304 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 28% | 1.15 | 22 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006211 | Biological process | 5-methylcytosine catabolic process |
GO_0006493 | Biological process | protein O-linked glycosylation |
GO_0044029 | Biological process | positive regulation of gene expression via chromosomal CpG island demethylation |
GO_0044727 | Biological process | epigenetic programing of male pronucleus |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0001939 | Cellular component | female pronucleus |
GO_0001940 | Cellular component | male pronucleus |
GO_0005694 | Cellular component | chromosome |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0008327 | Molecular function | methyl-CpG binding |
GO_0070579 | Molecular function | 5-methylcytosine dioxygenase activity |
GO_0005515 | Molecular function | protein binding |
GO_0008270 | Molecular function | zinc ion binding |
Gene name | TET3 |
Protein name | Methylcytosine dioxygenase TET (EC 1.14.11.80) Methylcytosine dioxygenase TET3 (EC 1.14.11.80) Alternative protein TET3 |
Synonyms | KIAA0401 |
Description | FUNCTION: Dioxygenase that catalyzes the conversion of the modified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and plays a key role in epigenetic chromatin reprogramming in the zygote following fertilization . Also mediates subsequent conversion of 5hmC into 5-formylcytosine (5fC), and conversion of 5fC to 5-carboxylcytosine (5caC). Conversion of 5mC into 5hmC, 5fC and 5caC probably constitutes the first step in cytosine demethylation (By similarity). Selectively binds to the promoter region of target genes and contributes to regulate the expression of numerous developmental genes . In zygotes, DNA demethylation occurs selectively in the paternal pronucleus before the first cell division, while the adjacent maternal pronucleus and certain paternally-imprinted loci are protected from this process. Participates in DNA demethylation in the paternal pronucleus by mediating conversion of 5mC into 5hmC, 5fC and 5caC. Does not mediate DNA demethylation of maternal pronucleus because of the presence of DPPA3/PGC7 on maternal chromatin that prevents TET3-binding to chromatin (By similarity). In addition to its role in DNA demethylation, also involved in the recruitment of the O-GlcNAc transferase OGT to CpG-rich transcription start sites of active genes, thereby promoting histone H2B GlcNAcylation by OGT . Binds preferentially to DNA containing cytidine-phosphate-guanosine (CpG) dinucleotides over CpH (H=A, T, and C), hemimethylated-CpG and hemimethylated-hydroxymethyl-CpG . . FUNCTION: Dioxygenase that catalyzes the conversion of the modified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and plays a key role in epigenetic chromatin reprogramming during embryonic development. . |
Accessions | ENST00000305799.8 A0A5H1ZRP3 L8EBE0 ENST00000409262.8 [O43151-1] O43151 |